Skip to main content

Published locations for Lenalidomide plus rituximab achieves 87% response rate

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Lenalidomide plus rituximab achieves 87% response rate

User login

  • Reset your password
  • /content/lenalidomide-plus-rituximab-achieves-87-response-rate
  • /edermatologynews/article/104133/mantle-cell-lymphoma/lenalidomide-plus-rituximab-achieves-87
  • /hematologynews/article/104133/mantle-cell-lymphoma/lenalidomide-plus-rituximab-achieves-87-response
  • /oncologypractice/article/104133/mantle-cell-lymphoma/lenalidomide-plus-rituximab-achieves-87
  • /hematology-oncology/article/104133/mantle-cell-lymphoma/lenalidomide-plus-rituximab-achieves-87
  • /dermatology/article/104133/mantle-cell-lymphoma/lenalidomide-plus-rituximab-achieves-87-response
  • /b-cell-lymphoma-icymi/article/104133/mantle-cell-lymphoma/lenalidomide-plus-rituximab-achieves-87